EnteroMedics Presses Towards Approval, Rollout Of Novel Obesity Device
This article was originally published in The Gray Sheet
During an April 30 earnings call, EnteroMedics Inc. discussed its plans for securing a PMA for its Maestro neuromodulation device targeting obese patients, and subsequent rollout, in advance of an FDA panel meeting.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.